British journal of cancer · 1997

High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Benedetti Panici P, Pierelli L, Scambia G, Foddai ML, Salerno MG, Menichella G, Vittori M, Maneschi F, Caracussi U, Serafini R, Leone G, Mancuso S

Аннотация

The present report describes the non-haematological toxicity and the influence of growth factor administration on haematological toxicity and haematopoietic recovery observed after high-dose carboplatin (1200 mg m(-2)), etoposide (900 mg m(-2)) and melphalan (100 mg m(-2)) (CEM) followed by peripheral blood progenitor cell transplantation (PBPCT) in 40 patients with high-risk cancer during their first-line treatment. PBPCs were collected during the previous outpatient induction chemotherapy programme by leukaphereses. CEM administration with PBPCT was associated with low non-haematological toxicity and the only significant toxicity consisted of a reversible grade III/IV increase in liver enzymes in 32% of the patients. Haematopoietic recovery was very fast in all patients and the administration of granulocyte colony-stimulating factor (G-CSF) plus erythropoietin (EPO) or granulocyte-macrophage colony-stimulating factor (GM-CSF) plus EPO after PBPCT significantly reduced haematological toxicity, abrogated antibiotic administration during neutropenia and significantly reduced hospital stay and patient's hospital charge compared with patients treated with PBPCT only. None of the patients died early of CEM plus PBPCT-related complications. Low non-haematological toxicity and accelerated haematopoietic recovery renders CEM with PBPC/growth factor support an acceptable therapeutic approach in an adjuvant or neoadjuvant setting.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Aisner J., Lee E. J. Etoposide. Current and future status. Cancer. 1991 Jan 1;67(1 Suppl):215–219. doi: 10.1002/1097-0142(19910101)67:1+<215::aid-cncr2820671302>3.0.co;2-d.

Antman K., Ayash L., Elias A., Wheeler C., Hunt M., Eder J. P., Teicher B. A., Critchlow J., Bibbo J., Schnipper L. E. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992 Jan;10(1):102–110. doi: 10.1200/JCO.1992.10.1.102.

Ayash L. J., Elias A., Wheeler C., Reich E., Schwartz G., Mazanet R., Tepler I., Warren D., Lynch C., Gonin R. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol. 1994 Jan;12(1):37–44. doi: 10.1200/JCO.1994.12.1.37.

Ayash L., Korbut T., Herman T. S., Teicher B. A. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells. Cancer Lett. 1991 Dec 9;61(1):7–14. doi: 10.1016/0304-3835(91)90070-x.

Barnett M. J., Coppin C. M., Murray N., Nevill T. J., Reece D. E., Klingemann H. G., Shepherd J. D., Nantel S. H., Sutherland H. J., Phillips G. L. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer. 1993 Sep;68(3):594–598. doi: 10.1038/bjc.1993.392.

Benedetti-Panici P., Greggi S., Scambia G., Salerno M. G., Baiocchi G., Laurelli G., Menichella G., Pierelli L., Foddai M. L., Serafini R. Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer. 1995 Nov;31A(12):1987–1992. doi: 10.1016/0959-8049(95)00337-1.

Bensinger W. I., Longin K., Appelbaum F., Rowley S., Weaver C., Lilleby K., Gooley T., Lynch M., Higano T., Klarnet J. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol. 1994 Aug;87(4):825–831. doi: 10.1111/j.1365-2141.1994.tb06744.x.

Bensinger W., Singer J., Appelbaum F., Lilleby K., Longin K., Rowley S., Clarke E., Clift R., Hansen J., Shields T. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood. 1993 Jun 1;81(11):3158–3163.

Castello M. A., Clerico A., Jenkner A., Dominici C. A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors. Pediatr Hematol Oncol. 1990;7(2):129–135. doi: 10.3109/08880019009033382.

Chao N. J., Schriber J. R., Grimes K., Long G. D., Negrin R. S., Raimondi C. M., Horning S. J., Brown S. L., Miller L., Blume K. G. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood. 1993 Apr 15;81(8):2031–2035.

Eder J. P., Elias A., Shea T. C., Schryber S. M., Teicher B. A., Hunt M., Burke J., Siegel R., Schnipper L. E., Frei E., 3rd A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol. 1990 Jul;8(7):1239–1245. doi: 10.1200/JCO.1990.8.7.1239.

Elias A. D., Ayash L. J., Eder J. P., Wheeler C., Deary J., Weissman L., Schryber S., Hunt M., Critchlow J., Schnipper L. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 1991 Feb;9(2):320–327. doi: 10.1200/JCO.1991.9.2.320.

Elias A. D., Ayash L. J., Wheeler C., Schwartz G., Tepler I., Gonin R., McCauley M., Mazanet R., Schnipper L., Frei E., 3rd Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant. 1995 Mar;15(3):373–379.

Elias A. D., Ayash L., Anderson K. C., Hunt M., Wheeler C., Schwartz G., Tepler I., Mazanet R., Lynch C., Pap S. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood. 1992 Jun 1;79(11):3036–3044.

Fields K. K., Elfenbein G. J., Perkins J. B., Janssen W. E., Ballester O. F., Hiemenz J. W., Zorsky P. E., Kronish L. E., Foody M. C. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion. Semin Oncol. 1994 Oct;21(5 Suppl 12):86–92.

Gaspard M. H., Maraninchi D., Stoppa A. M., Gastaut J. A., Michel G., Tubiana N., Blaise D., Novakovitch G., Rossi J. F., Weiller P. J. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol. 1988;22(3):256–262. doi: 10.1007/BF00273421.

Gianni A. M., Siena S., Bregni M., Tarella C., Stern A. C., Pileri A., Bonadonna G. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet. 1989 Sep 9;2(8663):580–585. doi: 10.1016/s0140-6736(89)90711-3.

Gianni A. M., Tarella C., Bregni M., Siena S., Lombardi F., Gandola L., Caracciolo D., Stern A., Bonadonna G., Boccadoro M. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol. 1994 Mar;12(3):503–509. doi: 10.1200/JCO.1994.12.3.503.

Henon P. R., Liang H., Beck-Wirth G., Eisenmann J. C., Lepers M., Wunder E., Kandel G. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant. 1992 Apr;9(4):285–291.

Ibrahim A., Zambon E., Bourhis J. H., Ostronoff M., Beaujean F., Viens P., Lhomme C., Chazard M., Maraninchi D., Hayat M. High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Eur J Cancer. 1993;29A(10):1398–1403. doi: 10.1016/0959-8049(93)90010-d.

Loehrer P. J., Sr, Einhorn L. H., Williams S. D. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol. 1986 Apr;4(4):528–536. doi: 10.1200/JCO.1986.4.4.528.

Lotz J. P., André T., Donsimoni R., Firmin C., Bouleuc C., Bonnak H., Merad Z., Esteso A., Gerota J., Izrael V. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer. 1995 Feb 1;75(3):874–885. doi: 10.1002/1097-0142(19950201)75:3<874::aid-cncr2820750320>3.0.co;2-q.

McMillan A. K., Goldstone A. H. Autologous bone marrow transplantation for non-Hodgkin's lymphoma. Eur J Haematol. 1991 Mar;46(3):129–135. doi: 10.1111/j.1600-0609.1991.tb01265.x.

Menichella G., Pierelli L., Foddai M. L., Paoloni A., Vittori M., Serafini R., Benedetti Panici P., Scambia G., Baiocchi G., Greggi S. Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. Br J Haematol. 1991 Nov;79(3):444–450. doi: 10.1111/j.1365-2141.1991.tb08053.x.

Menichella G., Pierelli L., Scambia G., Salerno G., Benedetti Panici P., Foddai M. L., Serafini R., Puglia G., Lai M., Ciarli M. Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer. Bone Marrow Transplant. 1994 Dec;14(6):907–912.

Nichols C. R., Tricot G., Williams S. D., van Besien K., Loehrer P. J., Roth B. J., Akard L., Hoffman R., Goulet R., Wolff S. N. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989 Jul;7(7):932–939. doi: 10.1200/JCO.1989.7.7.932.

Ozols R. F., Behrens B. C., Ostchega Y., Young R. C. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev. 1985 Sep;12 (Suppl A):59–65. doi: 10.1016/0305-7372(85)90019-2.

Peters W. P., Ross M., Vredenburgh J. J., Meisenberg B., Marks L. B., Winer E., Kurtzberg J., Bast R. C., Jr, Jones R., Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun;11(6):1132–1143. doi: 10.1200/JCO.1993.11.6.1132.

Pierelli L., Iacone A., Quaglietta A. M., Nicolucci A., Menichella G., Benedetti Panici P., D'Antonio D., De Laurenzi A., De Rosa L., Fioritoni G. Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicentre retrospective study. Br J Haematol. 1994 Jan;86(1):70–75. doi: 10.1111/j.1365-2141.1994.tb03254.x.

Pierelli L., Menichella G., Paoloni A., Vittori M., Foddai M. L., Serafini R., Rumi C., Mitschulat H., Rossi P. L., Scambia G. Evaluation of a novel automated protocol for the collection of peripheral blood stem cells mobilized with chemotherapy or chemotherapy plus G-CSF using the Fresenius AS104 cell separator. J Hematother. 1993 Summer;2(2):145–153. doi: 10.1089/scd.1.1993.2.145.

Piver M. S. Ovarian carcinoma. A decade of progress. Cancer. 1984 Dec 1;54(11 Suppl):2706–2715. doi: 10.1002/1097-0142(19841201)54:2+<2706::aid-cncr2820541417>3.0.co;2-l.

Sheridan W. P., Begley C. G., Juttner C. A., Szer J., To L. B., Maher D., McGrath K. M., Morstyn G., Fox R. M. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992 Mar 14;339(8794):640–644. doi: 10.1016/0140-6736(92)90795-5.

Shimazaki C., Oku N., Uchiyama H., Yamagata N., Tatsumi T., Hirata T., Ashihara E., Okawa K., Goto H., Inaba T. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 1994 Mar;13(3):271–275.

Sica S., Salutari P., Di Mario A., Rutella S., Ortu-LaBarbera E., Storti S., De Stefano V., Menichella G., Pierelli L., Zini G. Autologous transplantation of peripheral blood progenitor cells mobilized by chemotherapy with or without G-CSF (filgrastim) in resistant lymphoproliferative diseases: enhanced hemopoietic recovery with filgrastim primed progenitors. Haematologica. 1993 Nov-Dec;78(6):383–388.

Siegert W., Beyer J., Strohscheer I., Baurmann H., Oettle H., Zingsem J., Zimmermann R., Bokemeyer C., Schmoll H. J., Huhn D. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol. 1994 Jun;12(6):1223–1231. doi: 10.1200/JCO.1994.12.6.1223.

Slease R. B., Benear J. B., Selby G. B., Reitz C. L., Hughes W. L., Watkins C. L., Epstein R. B. High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol. 1988 Aug;6(8):1314–1320. doi: 10.1200/JCO.1988.6.8.1314.

Spitzer G., Adkins D. R., Spencer V., Dunphy F. R., Petruska P. J., Velasquez W. S., Bowers C. E., Kronmueller N., Niemeyer R., McIntyre W. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol. 1994 Apr;12(4):661–670. doi: 10.1200/JCO.1994.12.4.661.

Spitzer T. R., Cirenza E., McAfee S., Foelber R., Zarzin J., Cahill R., Mazumder A. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant. 1995 Apr;15(4):537–542.

To L. B., Roberts M. M., Haylock D. N., Dyson P. G., Branford A. L., Thorp D., Ho J. Q., Dart G. W., Horvath N., Davy M. L. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992 Apr;9(4):277–284.

Vincent M. D., Powles T. J., Coombes R. C., McElwain T. J. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol. 1988;21(3):255–260. doi: 10.1007/BF00262781.

Wheeler C., Strawderman M., Ayash L., Churchill W. H., Bierer B. E., Elias A., Gilliland D. G., Antman K., Guinan E. C., Eder J. P. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993 Jun;11(6):1085–1091. doi: 10.1200/JCO.1993.11.6.1085.

Williams S. F., Bitran J. D., Kaminer L., Westbrook C., Jacobs R., Ashenhurst J., Robin E., Purl S., Beschorner J., Schroeder C. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol. 1987 Feb;5(2):260–265. doi: 10.1200/JCO.1987.5.2.260.

Williams S. F., Gilewski T., Mick R., Bitran J. D. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol. 1992 Nov;10(11):1743–1747. doi: 10.1200/JCO.1992.10.11.1743.

de Graaf H., Willemse P. H., de Vries E. G., Sleijfer D. T., Mulder P. O., van der Graaf W. T., Smit Sibinga C. T., van der Ploeg E., Dolsma W. V., Mulder N. H. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer. 1994;30A(2):150–153. doi: 10.1016/0959-8049(94)90076-0.

van der Wall E., Nooijen W. J., Baars J. W., Holtkamp M. J., Schorangel J. H., Richel D. J., Rutgers E. J., Slaper-Cortenbach I. C., van der Schoot C. E., Rodenhuis S. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer. 1995 Apr;71(4):857–862. doi: 10.1038/bjc.1995.165.

High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.

Ошибки и ограничения

Аннотация

Selected References